logo
[breadcrumb_custom]

Day: December 19, 2020

ZM Stock
Stock Investing

How VEREIT (NYSE: VER) Stock shot up on Friday Morning?

So, What’s New The shares of VEREIT (NYSE: VER) closed Friday at around $37.86 in contrast with the previous close of $7,70. The calculation on that move, though, is meaningless. This price move was widely expected. Management announced plans to perform a 5-for-1 reverse stock split on Nov. 5, when it announced its third-quarter earnings. The number of shares doesn’t change with stock splits, only the number of shares. After the split, proportional ownership will remain the same among shareholders. Meanwhile, the dividend will now be $0.385 per share, a five-fold increase over what it was before the reverse split.   

PNC Stock
Trading Signals

What’s the update on Sundial Growers Inc. (Nasdaq: SNDL) Stock?

Sundial Growers Inc. (Nasdaq: SNDL) recently announced that it had repaid $50 million of its outstanding term loans to further strengthen the company’s balance sheet. All amounts are denominated in Canadian dollars unless noted. Repaying the debt will result in an annualized savings of $2.5 million in interest costs. The company’s indebtedness, including the Facility, is approximately $22 million. Its cash balance is currently about $39 million. Sundial’s Chief Financial Officer, Jim Keough, said the fast-tracked repayment of a significant portion of its debt is a further step toward advancing its financial flexibility and reducing its overall cost structure. Our

Stock Investing

Let’s take a look at why Aethlon Medical, Inc. (Nasdaq: AEMD) dropped its value

Aethlon Medical, Inc. (Nasdaq: AEMD), closed down -11.16% to $2.07 at the last close, after a clinical medical product and technology organization concentrating on unmet needs of infectious diseases, oncology and inflammation, confirmed that the first patient had been treated in the Company’s first-in-human Early Feasibility Study (EFS) applying the HEMOPURIFIER to patients with recurrent and metastatic squamous cell carcinoma of the neck. The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. EFS is an open-label, and a single-center trial is equivalent to Phase 1 clinical trials for drugs or biologics. The study evaluates the HEMOPURIFIER